Draft Guidance Issued for Injectors Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Draft Guidance Issued for Injectors Development


Equipment and Processing Report

To address the increasing popularity of drug-injector systems, the US Food and Drug Administration last week released a draft guidance for industry titled Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products.

The draft guidance applies to, but is not limited to, jet, pen, needle-free, and mechanically operated injectors as well as piston syringes and injectors with computerized or electronic elements. Injectors are categorized into three groups: those intended for use with a wide range of currently marketed drugs or biological products, those intended for use with a specific class or product line, and those intended for use with a specific product.

Depending on the system and its applications, these elements may fall under various regulatory provisions such as 21 CFR 3.2(e) or 510(k). The document discusses the scientific and technical considerations that may be relevant when developing these systems, regardless of the regulatory provisions that apply.

The draft guidance discusses design features as well as general use, conditions of use (e.g., personal use, use by healthcare professional, and disposable or reusable products), and injector materials used to construct or manufacture each device. The document provides a list of the various performance testing standards (ISO and ASTM) that are recommended and discusses separate tests such as biocompatibility, dose accuracy, shelf-life stability, and expiration dating. Sterilization and sterility testing is also discussed in detail.

A copy of the draft guidance can be downloaded for the purposes of providing a comment.

See related PharmTech articles:

S. Sutton, EPT, Prefilled Syringes Growing More Popular

N. Motlekar, Online Exclusive, Designing and Delivering Therapeutic Proteins

B. Harrison and M. Rios, May 2007, Big Shot: Developments in Prefilled Syringes

D. McCormick, Oct. 2006, Developing First Disposable Injector for a Biopharmaceutical

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Equipment and Processing Report,
Click here